Melinda Gooderham, MSc, MD, FRCPC

At AAD 2026, Melinda Gooderham, MSc, MD, FRCPC, reviewed late-breaking zasocitinib data for psoriasis, noting that 70% of patients reached sPGA 0/1.

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

Gooderham reviews key highlights from EADV 2024 on the ADjoin long-term extension trial for patients with moderate to severe AD.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.